Study: Long-Term Cannabis Use Associated With Reduced Prescriptions, Improved Symptoms in Cancer Patients
Israeli researchers assessed the long-term use of cannabis in a cohort of several hundred oncology patients.
Consistent with studies of other patient cohorts, cannabis use was associated with symptom mitigation, improved quality of life, and reduced prescription drug use. Among those participants who completed the trial, nearly half ceased their use of analgesics.
Authors concluded: “The main finding of the current study is that most cancer comorbid symptoms improved significantly during six months of MC [medical cannabis] treatment. … Additionally, we found that MC treatment in cancer patients was well tolerated and safe. … In conclusion, this prospective, comprehensive and large-scale cohort demonstrated an overall mild to modest long-term statistical improvement of all investigated measures including pain, associated symptoms and, importantly, reduction in opioid (and other analgesics) use.”
Full text of the study, “The effectiveness and safety of medical cannabis for treating cancer related symptoms in oncology patients,” appears inFrontiers in Pain Research. Additional information is available from the NORML fact sheet, “Relationship Between Marijuana and Opioids.”
Latest News
Cannabis Extraction Market: An In-depth Analysis from 2018-2027
Douglas, Isle Of Man - Cannabis extraction and extract have gone through exponential growth in the past decade. After being criminalized for a long time, the world saw and moved towards legalizing cannabis in many ...
Bright Green Issues Statement of Intent on Illegal Short Selling Activities
GRANTS, N.M. - Bright Green Corporation (NASDAQ: BGXX) (“Bright Green” or “the Company”), one of the very few companies selected by the U.S. government to grow, manufacture, and sell, legally under federal and state laws, ...
Global Cannabis Testing Market Analysis Report 2023-2030
DUBLIN - Global Cannabis Testing Market to Reach $2.8 Billion by 2030 In the changed post COVID-19 business landscape, the global market for Cannabis Testing estimated at US$1.1 Billion in the year 2022, is projected to reach ...